Table 2.
Seroprevalence of poliovirus antibodies in per-protocol infants (n=554)
| Group A: mOPV1–1 week (N=135) |
Group B: mOPV1–2 weeks (N=135) |
Group C: mOPV1–4 weeks (N=148) |
Group D: bOPV 1 and 3–4 weeks (N=136) |
p value
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| A vs C | A vs D | B vs C | B vs D | C vs D | |||||
| At birth | |||||||||
|
| |||||||||
| Type-1 poliovirus | 125/135 (93%) | 132/135 (98%) | 135/148 (91%) | 129/136 (95%) | 0.961 | 0.860 | 0.092 | 0.738 | 0.566 |
| Reciprocal titres | 113.8 (22.6–227.5), 72.0–126.1 | 90.5 (28.4–227.5), 72.0–113.8 | 68.0 (18.0–181.0), 41.2–100.8 | 90.5 (28.4–343.5), 58.1–178.1 | 0.163 | 0.671 | 0.374 | 0.667 | 0.318 |
| Type-2 poliovirus | 125/135 (93%) | 126/135 (93%) | 135/148 (91%) | 125/136 (92%) | 0.973 | 0.997 | 0.911 | 0.972 | 0.996 |
| Reciprocal titres | 90.5 (22.6–288.0), 56.9–113.8 | 90.5 (22.6–362.0), 83.0–181.0 | 56.9 (14.2–227.5), 28.4–90.5 | 90.5 (14.2–288.0), 56.9–144.0 | 0.185 | 0.851 | 0.099 | 0.586 | 0.131 |
| Type-3 poliovirus | 102/135 (76%) | 99/135 (73%) | 113/148 (76%) | 106/136 (78%) | 0.999 | 0.968 | 0.935 | 0.814 | 0.990 |
| Reciprocal titres | 18.0 (9.0–144.0), 14.2–28.4 | 18.0 (7.1–72.0), 14.2–28.4 | 22.6 (9.0–90.5), 18.0–36.0 | 22.6 (9.0–113.8), 14.2–31.7 | 0.479 | 0.503 | 0.278 | 0.670 | 0.374 |
|
| |||||||||
| Age 42 days | |||||||||
|
| |||||||||
| Type-1 poliovirus | 120/135 (89%) | 126/135 (93%) | 129/148 (87%) | 124/136 (91%), 45.3–113.8 | 0.962 | 0.923 | 0.307 | 0.934 | 0.671 |
| Reciprocal titres | 56.9 (18.0–288.0), 41.5–90.5 | 56.9 (18.0–288.0), 36.0–72.0 | 45.3 (11.3–288.0), 28.4–90.5 | 90.5 (18.0–288.0) | 0.789 | 0.248 | 0.679 | 0.129 | 0.131 |
| Type-2 poliovirus | 127/135 (94%) | 129/135 (96%), | 136/148 (92%) | 120/136 (88%), 113.8–362.0 | 0.899 | 0.266 | 0.649 | 0.104 | 0.649 |
| Reciprocal titres | 181.0 (36.0–910.2), 113.8–362.0 | 113.8 (36.0–1152.1), 90.5–288.0 | 288.0 (45.3–1152.1), 181.0–455.1 | 227.5 (24.1–1152.1) | 0.425 | 0.948 | 0.194 | 0.247 | 0.464 |
| Type-3 poliovirus | 74/135 (55%) | 78/135 (58%) | 86/148 (58%) | 81/136 (60%), | 0.944 | 0.860 | 0.99 | 0.991 | 0.995 |
| Reciprocal titres | 11.3 (5.7–56.9), 7.1–18.0 | 11.3 (5.7–90.5), 7.1–14.2 | 11.3 (5.7–90.5), 8.2–14.2 | 11.3 (57–85.9) | 0.907 | 0.668 | 0.622 | 0.426 | 0.748 |
|
| |||||||||
| At completion | |||||||||
|
| |||||||||
| Type-1 poliovirus | 132/135 (98%) | 131/135 (97%) | 143/148 (97%) | 126/136 (93%) | 0.959 | 0.134 | 0.998 | 0.250 | 0.316 |
| Reciprocal titres | 910.2 (181.0–1448.2), 663.9–1152.1 | 910.2 (144.0–1448.2), 663.9–1152.1 | 910.2 (288.0–1448.2), 724.1–1152.1 | 817.1 (121.3–1448.2), 455.1–1152.1 | 0.739 | 0.948 | 0.968 | 0.763 | 0.789 |
| Type-2 poliovirus | 111/135 (82%) | 105/135 (78%) | 117/148 (79%) | 107/136 (79%) | 0.913 | 0.889 | 0.994 | 0.998 | 0.999 |
| Reciprocal titres | 181.0 (11.3–1152.1), 56.9–399.9 | 227.5 (9.0–1152.1), 32.9–504.2 | 362.0 (12.0–1448.2), 130.6–724.1 | 371.6 (11.3–1448.2), 92.3–576.0 | 0.245 | 0.584 | 0.590 | 0.761 | 0.649 |
| Type-3 poliovirus | 60/135 (44%) | 50/135 (37%) | 65/148 (44%) | 107/136 (79%), | 0.999 | <0.0001 | 0.616 | <0.0001 | <0.0001 |
| Reciprocal titres | 5.7 (5.7–72.0), 5.7–9.9 | 5.7 (5.7–45.3), 5.7–5.8 | 5.7 (5.7–136.4), 5.7–9.0 | 181.0 (9.0–910.2), 90.5–455.1 | 0.695 | <0.0001 | 0.173 | <0.0001 | <0.0001 |
Data are n/N (%) for proportion of infants with seroprevalence, and median (IQRs) and 95% CIs for reciprocal titres in these infants. mOPV1=monovalent oral polio vaccine type 1. bOPV1 and 3=bivalent OPV type 1 and 3. mOPV1–1 week=1 week interval between two doses of mOPV1. mOPV1–2 weeks=2 week interval between two doses of mOPV1. mOPV1–4 weeks=4 week interval between two doses of mOPV1. bOPV1 and 3–4 weeks=4 week interval between two doses of bOPV1 and 3.